Abstract
The X-linked neurodevelopmental diseases CDKL5 deficiency disorder (CDD) and Rett syndrome (RTT) are associated with intellectual disability, infantile spasms and seizures. Although mitochondrial dysfunction has been suggested in RTT, less is understood about mitochondrial function in CDD. A comparison of bioenergetics and mitochondrial function between isogenic wild-type and mutant neural progenitor cell (NPC) lines revealed increased oxygen consumption in CDD mutant lines, which is associated with altered mitochondrial function and structure. Transcriptomic analysis revealed differential expression of genes related to mitochondrial and REDOX function in NPCs expressing the mutant CDKL5. Furthermore, a similar increase in oxygen consumption specific to RTT patient-derived isogenic mutant NPCs was observed, though the pattern of mitochondrial functional alterations was distinct from CDKL5 mutant-expressing NPCs. We propose that aberrant neural bioenergetics is a common feature between CDD and RTT disorders. The observed changes in oxidative stress and mitochondrial function may facilitate the development of therapeutic agents for CDD and related disorders.
| Original language | English |
|---|---|
| Pages (from-to) | 3625-3636 |
| Number of pages | 12 |
| Journal | Human Molecular Genetics |
| Volume | 28 |
| Issue number | 21 |
| DOIs | |
| State | Published - 1 Nov 2019 |
| Externally published | Yes |
Bibliographical note
Funding Information:Authors thank Mriganka Sur (Department of Brain and Cognitive Sciences, MIT) for providing RTT isogenic iPSCs, Jayla Ruliera (Center for Genomic Medicine, MGH) for technical assistance with deriving patient fibroblast cultures for iPSC reprogramming and Diane Capen (Center for Systems Biology, MGH) for technical assistance in TEM sample preparation and imaging. This work was supported by a National Institute of Mental Health/National Human Genome Research Institute Center for Excellence in Genomic Science award [grant number P50 MH106933 to I.K. and R.H.P.] with preliminary support from the LouLou Foundation [R.H.P. and J.T.L.].
Funding Information:
Conflict of Interest statement. Dr. Perlis has served on advisory boards or provided consulting to Genomind, Psy Therapeutics, RIDVentures and Takeda. He receives salary support from JAMA Network-Open for service as associate editor. He holds equity in Psy Therapeutics and Outermost Therapeutics. He reports research support from the National Institute of Mental Health, National Heart, Lung and Blood Institute, National Center for Complementary and Integrative Health and National Human Genomics Research Institute. The other authors have declared that no conflicts of interest exist.
Publisher Copyright:
© 2019 Published by Oxford University Press 2019. This work is written by (a) US Government employee(s) and is in the public domain in the US.